Search
NIP has seen poor vaccine impact, related to recent vaccine safety concerns.
We assessed the safety of receiving an influenza vaccination during any trimester of pregnancy with respect to preterm births and infant birthweight.
This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season
This study aimed to determine whether chronic, low-dose exposure to geogenic particulate matter <10μm diameter (PM10) exacerbates viral infections of the...
This paper reports the results from the safety surveillance of influenza vaccines in children in Australia, in 2015.
This study was designed to compare data collected via SMS and telephone for the purposes of monitoring vaccine safety.
Evidence is emerging of benefit to the infant with respect to preventing influenza infection in the first 6 months of life. The FluMum study aims to...
During the early phases of the 2009 pandemic, subjects with influenza-like illness only had laboratory testing specific for the new A(H1N1)pdm09 virus.
BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19.
Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.